CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Atai Life Sciences N v   (ATAI)
Other Ticker:  
 

Atai Life Sciences N V 's Quick Ratio

ATAI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 10.77 a new company low.

Within Major Pharmaceutical Preparations industry 92 other companies have achieved higher Quick Ratio than Atai Life Sciences N V in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 291 to 309.

Explain Quick Ratio?
How much Cash & cash equivalents ATAI´s has?
What are ATAI´s Current Liabilities?


ATAI Quick Ratio (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -25.12 % -19.83 % -11.11 % -4.96 % 69.18 %
Y / Y Cash & cash equivalent Change -31.26 % -27.2 % -25.39 % -24.61 % -29.34 %
Quick Ratio MRQ 10.77 12.92 12.73 13.73 11.73
ATAI's Total Ranking # 309 # 291 # 314 # 307 # 409
Seq. Current Liabilities Change 10.22 % -10.35 % -1.31 % -23.22 % 18.02 %
Seq. Cash & cash equivalent Change -8.13 % -8.96 % -8.5 % -10.18 % -2.7 %

New: More ATAI's historic Quick Ratios >>


Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 93
Healthcare Sector # 156
Overall Market # 308


Quick Ratio Statistics
High Average Low
31.98 16.86 10.77
(Jun 30 2021)   (Sep 30 2023)




Financial Statements
Atai Life Sciences N V 's Current Liabilities $ 19 Millions Visit ATAI's Balance sheet
Atai Life Sciences N V 's Cash & cash equivalent $ 209 Millions Visit ATAI's Balance sheet
Source of ATAI's Sales Visit ATAI's Sales by Geography


Cumulative Atai Life Sciences N V 's Quick Ratio

ATAI's Quick Ratio for the trailling 12 Months

ATAI Quick Ratio

 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -25.12 % -19.83 % -11.11 % -4.96 % 69.18 %
Y / Y Cash & cash equivalent TTM Growth -31.26 % -27.2 % -25.39 % -24.61 % -29.34 %
Quick Ratio TTM 12.54 12.7 13.04 13.63 14.45
Total Ranking TTM # 3026 # 2999 # 2883 # 3420 # 184
Seq. Current Liabilities TTM Growth 10.22 % -10.35 % -1.31 % -23.22 % 18.02 %
Seq. Cash & cash equivalent TTM Growth -8.13 % -8.96 % -8.5 % -10.18 % -2.7 %

Quick ratio ranking by company, industry and sector >> Back to ATAI Financial Strength Comparisons >> Go to Compare ATAI Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ATAI's Current Liabilities to $19.40 millions, cumulative Quick Ratio to 12.54 below the ATAI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 475 other companies have achieved higher Quick Ratio than Atai Life Sciences N V . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2999 to 3026.

Explain Quick Ratio?
How much Cash & cash equivalents ATAI´s has?
What are ATAI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 476
Healthcare Sector # 952
Within the Market # 3026


trailing twelve months Quick Ratio Statistics
High Average Low
21.8 15.41 12.38
(Mar 31 2022)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Aprea Therapeutics Inc   29.39 $ 25.354  Millions$ 0.863  Millions
Theseus Pharmaceuticals Inc   29.29 $ 205.122  Millions$ 7.003  Millions
Viking Therapeutics Inc   28.75 $ 376.241  Millions$ 13.086  Millions
Karuna Therapeutics Inc   27.40 $ 1,341.510  Millions$ 48.968  Millions
Atossa Therapeutics Inc   27.33 $ 94.141  Millions$ 3.444  Millions
Disc Medicine Inc   25.70 $ 370.541  Millions$ 14.416  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.17 $ 349.712  Millions$ 14.471  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Design Therapeutics Inc   23.48 $ 290.940  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.08 $ 5.106  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.23 $ 46.465  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.06 $ 266.600  Millions$ 12.087  Millions
Cyteir Therapeutics Inc   21.65 $ 129.242  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.64 $ 241.902  Millions$ 11.180  Millions
Xenon Pharmaceuticals Inc   21.28 $ 526.674  Millions$ 24.744  Millions
Tyra Biosciences Inc   21.25 $ 215.652  Millions$ 10.147  Millions
Astria Therapeutics inc   21.23 $ 188.806  Millions$ 8.894  Millions
Sagimet Biosciences inc   20.59 $ 101.842  Millions$ 4.946  Millions
Eledon Pharmaceuticals Inc   20.56 $ 59.609  Millions$ 2.899  Millions
Acelyrin Inc   20.41 $ 381.738  Millions$ 18.702  Millions
Akero Therapeutics Inc   19.50 $ 554.732  Millions$ 28.447  Millions
Acasti Pharma Inc   19.33 $ 27.006  Millions$ 1.397  Millions
Pliant Therapeutics Inc   19.11 $ 523.612  Millions$ 27.395  Millions
Eqrx Inc   19.03 $ 1,212.933  Millions$ 63.726  Millions
Pmv Pharmaceuticals Inc   18.84 $ 201.918  Millions$ 10.716  Millions
Ideaya Biosciences Inc   18.83 $ 468.751  Millions$ 24.893  Millions
Savara Inc   18.77 $ 168.251  Millions$ 8.963  Millions
Medicinova Inc   18.38 $ 51.507  Millions$ 2.802  Millions
Immuneering Corporation  18.28 $ 97.243  Millions$ 5.321  Millions

Date modified: 2023-11-16T18:28:42+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com